MedPath

Estramustine

Generic Name
Estramustine
Brand Names
Emcyt
Drug Type
Small Molecule
Chemical Formula
C23H31Cl2NO3
CAS Number
2998-57-4
Unique Ingredient Identifier
35LT29625A
Background

A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Indication

For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate

Associated Conditions
Metastatic Prostate Cancer
Associated Therapies
-
Clinical Trials
Related News

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Etoposide
Drug: Paclitaxel
First Posted Date
2005-09-08
Last Posted Date
2015-01-21
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
28
Registration Number
NCT00151060
Locations
🇺🇸

The University of Michigan Comprehensive Cancer, Ann Arbor, Michigan, United States

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Phase 2
Completed
Conditions
Hormone-Refractory Prostate Cancer
Interventions
Drug: Zoledronic acid
Drug: Estramustine
Drug: Docetaxel
First Posted Date
2005-09-08
Last Posted Date
2015-01-22
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
28
Registration Number
NCT00151073
Locations
🇺🇸

The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Vinorelbine
First Posted Date
2005-09-08
Last Posted Date
2015-01-22
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
33
Registration Number
NCT00151086
Locations
🇺🇸

The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Phase 2
Completed
Conditions
Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Interventions
Drug: estramustine phosphate sodium
Drug: docetaxel
Biological: bevacizumab
Other: laboratory biomarker analysis
First Posted Date
2003-06-10
Last Posted Date
2013-06-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
72
Registration Number
NCT00016107
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-07-16
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
41
Registration Number
NCT00028769
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

CCOP - Atlanta Regional, Atlanta, Georgia, United States

🇺🇸

CCOP - Central Illinois, Decatur, Illinois, United States

and more 88 locations

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: docetaxel
Drug: mitoxantrone
Drug: estramustine
Drug: prednisone
First Posted Date
2003-01-27
Last Posted Date
2014-02-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
770
Registration Number
NCT00004001
Locations
🇺🇸

CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States

🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

🇺🇸

CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 13 locations

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: carboplatin
Drug: estramustine
Drug: paclitaxel
Radiation: radiation therapy
Drug: leuprolide or goserelin acetate
First Posted Date
2003-01-27
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
34
Registration Number
NCT00016913
Locations
🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

🇺🇸

Bon Secours St. Francis Health System, Greenville, South Carolina, United States

🇺🇸

CCOP - Greenville, Greenville, South Carolina, United States

and more 20 locations

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Thalidomide
Drug: Paclitaxel (Taxol)
First Posted Date
2002-05-30
Last Posted Date
2018-10-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT00038246
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
Drug: Estramustine
Drug: Taxol
First Posted Date
2002-05-30
Last Posted Date
2012-08-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
14
Registration Number
NCT00038168
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy